PatientPlus articles are written by UK doctors and are based on research evidence, UK and European Guidelines. They are designed for health professionals to use, so you may find the language more technical than the condition leaflets.
Synonyms: renovascular occlusive disease, renal vascular disease, atherosclerotic/atheromatous renal artery disease, atherosclerotic renovascular disease (ARVD), renal artery stenosis, renovascular hypertension, ischaemic nephropathy, renal artery fibromuscular hyperplasia
Renovascular disease is the term given to the impairment of renal perfusion caused by disease affecting the arterial supply of the kidney(s). Renal hypoperfusion leads to hyperactivation of the renin-angiotensin-aldosterone axis, causing hypertension. Renal vascular disease is an important cause of secondary hypertension and chronic kidney disease.
Renal vein thrombosis may cause a similar pattern of disease and is discussed in a separate article Renal Vein Thrombosis.
- In the developed world, atherosclerosis is by far the most common cause of renovascular disease. This normally develops at the renal artery ostium on the luminal surface of the aorta/proximal renal artery. The atheroma obstructs renal blood flow and leads to chronic renal ischaemia. Atheroma may account for >90% of cases in white vascular high-risk populations. Renal artery atheroma is commonly associated with more generalised atheroma and cerebral, cardiac and/or peripheral vascular disease.
- In the Indian sub-continent and the Far East, Takayasu's arteritis is responsible for about 60% of cases.
- The remainder of renovascular disease is largely due to fibromuscular dysplasia of the renal artery which tends to affect the more distal portions of the renal artery. Fibromuscular dysplasia is an angiopathy of uncertain aetiology that may affect the carotid and vertebral circulation, visceral arteries, and peripheral arteries. Some series estimate that fibromuscular dysplasia may make up to 30% of cases of renal artery stenosis in vascular low-risk groups.
- Both atheroma and fibromuscular dysplasia cause unilateral renal artery stenosis in about 75% of cases.
Possible causes of renal hypoperfusion
- Renal artery atheroma/arteriosclerosis.
- Fibromuscular dysplasia of the renal artery.
- Prolonged hypotension or severe dehydration (usually transient but may cause permanent damage).
- Embolic renal disease.
- Renal artery or aortic dissection.
- Renal arteriovenous malformation.
- Takayasu's arteritis.
- Other arteritides, eg polyarteritis nodosa.
- Post-transplant renal artery stenosis.
- Post-radiotherapy renal artery disease.
- The exact prevalence is difficult to estimate, as the condition may easily go undiagnosed among hypertensive patients, and there is an appreciable prevalence of undiagnosed hypertension in the population at large.
- In the USA it is estimated to account for 1-5% of cases of secondary hypertension in the general population, but as much as 30% in vascular high-risk groups, or up to 60% in those aged >70 years.
- In a study of UK type 2 diabetics with hypertension (a high-risk group for renovascular disease) and normal serum creatinine levels, using magnetic resonance angiography to detect the disease, a prevalence of 17% was found. 95% of these patients had unilateral disease.
- The prevalence of angiographic renal artery stenosis in a group of UK patients undergoing angiography for suspected peripheral vascular disease was 36%.
- Atherosclerotic disease is most common among older men.
- Fibromuscular disease is most common among women aged 30-40 years. It can also be a cause of secondary hypertension in children.
- Renal artery stenosis is more common in Caucasian than in Afro-Caribbean populations.
- Hypertension (but up to 35% of patients with renovascular disease may be normotensive).
- Advanced age (much more common in those aged 60-70 years, with prevalence increasing in those aged >70 years; one unselected postmortem series showed a prevalence of 42% in those aged over 75 years).
- Evidence of renal impairment.
- Evidence of peripheral vascular or cerebrovascular/cardiovascular disease.
- Diabetes mellitus.
- Family history of cardiovascular disease or renovascular disease.
- White racial background (approximately twice the prevalence in those with a white racial background compared with African Americans in a group of patients with severe hypertension).
The condition may present in a variety of ways and is usually asymptomatic. The following clinical scenarios are relatively common modes of presentation:
- Abrupt onset of hypertension in middle-aged or older patients.
- Severe hypertension.
- Hypertension resistant to standard medical therapy.
- Hypertension developing in a patient with known peripheral-vascular/cerebrovascular/cardiovascular disease.
- Hypertension developing in a patient with no family history of hypertension.
- Biochemical or clinical evidence of renal impairment occurring during treatment with angiotensin-converting enzyme (ACE) inhibitors or angiotensin-II receptor antagonists.
- De novo renal impairment developing in a hypertensive or normotensive patient with vascular disease/risk factors.
- De novo hypertension or renal impairment developing in an older patient who has been previously normotensive.
- Hypertension with hypokalaemia (due to hyperaldosteronism) with no provoking medications or other identifiable cause (may be associated with metabolic acidosis).
- Decompensation of congestive cardiac failure in a hypertensive patient (may present with recurrent episodes of acute pulmonary oedema with no obvious precipitant - so-called 'flash pulmonary oedema').
- Look for evidence of vascular risk factors such as corneal arcus in younger patients, xanthomata, xanthelasmata, elevated blood pressure, etc.
- Look at general appearance: is there any evidence of other causes of secondary hypertension, such as Cushing's syndrome?
- Check for radiofemoral delay and also check blood pressure in both arms to look for aortic coarctation/dissection.
- Palpate peripheral and carotid pulses and auscultate for bruits to look for evidence of generalised vascular disease (the presence of which greatly increases the likelihood that hypertension is due to renovascular disease).
- An abdominal bruit, also heard over the flank, is a relatively common finding in patients with renovascular hypertension, being found in up to 50% of patients with the disease. However, up to 10% of patients with essential primary hypertension may have an abdominal bruit and innocent abdominal bruits are present in a minority of healthy younger patients, so it is not a pathognomonic sign.
- The presence of a systolic-diastolic bruit in a hypertensive patient is highly suggestive of renovascular disease.
- The cardiovascular system should be examined to detect any evidence of cardiac failure or to identify other causes of secondary hypertension.
- Perform ophthalmoscopy to look for evidence of hypertensive retinopathy, indicating long-standing hypertension, or to reveal evidence of occult diabetes.
- Dipstick urine for glucose and protein (mild-to-moderate proteinuria is sometimes a feature).
- Essential primary hypertension.
- Any other cause of renal impairment, particularly glomerulonephritis.
- Iatrogenic renal impairment.
- Other causes of secondary hypertension.
- Malignant primary or secondary hypertension.
- Acute interstitial nephritis caused by medication, autoimmunity or hypersensitivity phenomenon following infection.
- Other causes of hypertension and albuminuria.
- Collagen vascular diseases.
- Arteritides (may cause renovascular disease or present similarly without affecting renal blood flow).
When to refer to secondary care
- Refractory hypertension (ie blood pressure >150/90 mm Hg despite 3 antihypertensive agents).
- Recurrent episodes of pulmonary oedema despite normal left ventricular function on echocardiography (so-called 'flash pulmonary oedema', usually associated with hypertension).
- Rising serum creatinine concentration (rise of ≥20% or fall of glomerular filtration rate (GFR) >15%):
- Over 12 months with a high clinical suspicion of widespread atherosclerosis.
- Or during the first 2 months after initiation of treatment with an ACE inhibitor or angiotensin receptor blocker.
- Unexplained hypokalaemia with hypertension.
Urine and blood tests
- Blood for renal function tests (including eGFR) and electrolytes.
- Blood glucose.
- 24-hour urinary protein excretion and tests for microalbuminuria may aid in the decision-making process.
- Urinalysis to exclude the presence of red blood cells/red blood cell casts which can be found in glomerulonephritis.
- Serology to exclude systemic lupus erythematosus or vasculitis if suspected (eg antinuclear antibodies, complement, etc.).
- Lipid profile, as renovascular disease is likely to be part of more extensive atherosclerotic disease.
- Renal ultrasound is often performed in those with renal impairment but it is not diagnostic for renovascular disease. The diagnosis is suggested if there is a significant difference in kidney size (>1.5 cm).
- Duplex renal ultrasound combines ultrasound and doppler techniques and can be a good diagnostic test. However, it is labour intensive and technician-dependent.
- If there is a high clinical index of suspicion of renovascular disease that may be amenable to intervention, conventional angiography should be considered to make the diagnosis. However, there is a risk of complications such as arterial puncture and catheter-induced atheroembolism. It has the advantage that endovascular therapy can be carried out at the same time.
- CT angiography uses intravenous injection of contrast material to allow images of the renal arteries. There is a risk of contrast-associated nephropathy.
- Magnetic resonance angiography allows direct visualisation of renal artery lesions and can be used to assess blood flow rate, GFR and renal perfusion rate. However, it has only been validated for disease in the proximal renal arteries.
- Radionuclide scanning following a dose of captopril can be helpful if fibromuscular disease is suspected in patients with normal renal function.
- Selective renal vein renin measurements, plasma renin activity and the captopril test (measuring plasma renin activity after administration of captopril) were used in the past but are no longer thought to be useful screening tests.
Fibromuscular dysplasia is a pathological diagnosis. However, there are characteristic changes that can be seen on angiography in one form of fibromuscular dysplasia: medial fibroplasia. This is known as the 'string-of-beads appearance', caused by areas of relative stenoses or webs alternating with small fusiform or saccular aneurysms of the artery.
- Arteritides, particularly Takayasu's and polyarteritis nodosa.
- Diabetes mellitus.
- Fibromuscular dysplasia of the renal artery is possibly associated with alpha-1-antitrypsin deficiency.
Renal artery stenosis
General advice includes:
- Optimise vascular risk profile through smoking cessation, diabetes control, statins and adequate antihypertensive therapy.
- Avoid, or be very cautious in the use of, ACE inhibitors and angiotensin-II receptor antagonists.
- Avoid other potentially nephrotoxic medications where possible, or adjust the dose as advised by formulary, eg non-steroidal anti-inflammatory drugs (NSAIDs) and renally excreted drugs.
- Seek expert advice if blood pressure cannot be controlled or vascular intervention is considered.
The management of renal artery stenosis can include:
- Medical management with drugs and vascular risk profile optimisation as above.
- Vascular intervention techniques, including angioplasty ± stenting.
Renal physicians are best placed to determine if or when vascular intervention is required in renal artery stenosis. This is an area that is controversial and is undergoing much research at present. It will depend on a number of factors, including local facilities and expertise, coexistent disease, the degree of renal impairment and the rate of progression of renal disease.
Angioplasty with stenting is generally used as the first line in vascular intervention. Open/endovascular surgery to reconstruct the stenosed artery and bypass procedures are also used. The current chronic kidney disease guidelines state that, with regards to angioplasty, it is generally accepted that:
- It is indicated in flash pulmonary oedema.
- It should be considered in refractory/severe hypertension.
Recent studies have shown that medication without angioplasty is preferable for most patients with clinically stable atherosclerotic renal artery stenosis.
- For patients with fibromuscular disease, the results of percutaneous vascular intervention are generally superior to those of drug therapy alone. Blood pressure outcome after angioplasty is generally better in patients with fibromuscular renal artery disease (who usually do not have renal failure) than for those with atherosclerotic renal artery stenosis.
- Percutaneous transluminal angioplasty with balloon dilatation ± stenting is the treatment of choice for fibromuscular disease.
- Vascular surgical reconstruction may also be used.
The evidence for best management
A recent systematic review of 55 relevant studies found that there were no studies directly comparing modern drug treatments for renal artery stenosis with modern angioplasty techniques, including stenting. The review concluded that there was insufficient evidence to support one treatment approach clearly over another for renal artery stenosis.
A large multicentre trial, testing treatment strategies for renal artery stenosis, is currently underway in the USA, comparing optimum medical therapy alone, to stenting with optimum medical therapy.
Another trail, the Angioplasty and Stent for Renal Artery Lesions (ASTRAL) trial, has also been designed to look at whether renal artery revascularisation with balloon angioplasty and/or stenting prevents progressive renal failure in those with renal artery stenosis. See 'Internet and further reading' section below for the link.
A Cochrane review looked at balloon angioplasty versus medical treatment for renal artery stenosis. It found that balloon angioplasty is superior to medical therapy in lowering blood pressure of people with renal artery stenosis and pharmacologically controlled blood pressure. However, where hypertension is refractory to medical therapy, there was weak evidence that balloon angioplasty lowers blood pressure more effectively than medical therapy. It concluded that randomised controlled trials are needed to compare the effect of balloon angioplasty and medical therapy on the preservation of renal function in the long term.
- End-organ damage from uncontrolled hypertension.
- Progressive chronic renal failure.
- Acute renal failure in rapidly advancing cases, or if there is intercurrent illness or other cause of renal insult.
- Deterioration in renal function in patients taking ACE inhibitors and angiotensin-II receptor antagonists.
- Refractory heart failure or episodic recurrent pulmonary oedema.
- Refractory angina.
- Atherosclerotic renal artery stenosis is often present in people with atherosclerosis elsewhere and is independently associated with an increased cardiovascular morbidity and mortality.
- The American Heart Association Committee on Diagnostic and Interventional Cardiac Catheterisation, Council on Clinical Cardiology, and the Councils on Cardiovascular Radiology and Intervention and on Kidney in Cardiovascular Disease suggest screening for renal artery stenosis in those who are candidates for coronary revascularisation.
- The prognosis is variable depending upon the severity of lesions, whether unilateral or bilateral, comorbidities and coexisting atherosclerotic disease, age, and response to medical or surgical therapy.
- One old study involving 169 patients with atherosclerotic and/or fibromuscular disease, looked at progression of the disease over a 10-year period. Progression of atherosclerotic disease was seen in about 44%. Deterioration to complete renal artery occlusion affected 16% of patients with atherosclerotic disease. Progression was seen in 33% with fibromuscular disease.
- For atheromatous vascular disease, see separate articles Primary Prevention of Cardiovascular Disease and Cardiovascular Risk Assessment.
- The deleterious effects of ACE inhibitors and angiotensin-II receptor antagonists in these patients mean that they should be avoided, or used with great caution, preferably with specialist advice.
Further reading & references
- Hirsch A et al; ACC/AHA Guidelines for the management of patients with peripheral arterial disease. J Am Coll Cardiol 2006 Mar 21;47(6):1239-312 - Full Text
- ASTRAL; Angioplasty and Stent for Renal Artery Lesions
- Schmidt RJ et al; Renovascular Hypertension, eMedicine, Sep 2009
- Spinowitz BS et al; Renal Artery Stenosis, eMedicine, Apr 2010
- Cheung CM, Hegarty J, Kalra PA; Dilemmas in the management of renal artery stenosis. Br Med Bull. 2005 Sep 7;73-74:35-55. Print 2005.
- Khan AN et al; Fibromuscular Dysplasia (Visceral Arteries), eMedicine, May 2008
- Valabhji J, Robinson S, Poulter C, et al; Prevalence of renal artery stenosis in subjects with type 2 diabetes and coexistent hypertension. Diabetes Care. 2000 Apr;23(4):539-43.
- Metcalfe W, Reid AW, Geddes CC; Prevalence of angiographic atherosclerotic renal artery disease and its relationship to the anatomical extent of peripheral vascular atherosclerosis. Nephrol Dial Transplant. 1999 Jan;14(1):105-8.
- UK Guidelines for the management of Chronic Kidney Disease, The Renal Association, January 2009
- Wargo KA, Chong K, Chan EC; Acute renal failure secondary to angiotensin II receptor blockade in a patient with bilateral renal artery stenosis. Pharmacotherapy. 2003 Sep;23(9):1199-204.
- Plouin PF, Bax L; Diagnosis and treatment of renal artery stenosis. Nat Rev Nephrol. 2010 Mar;6(3):151-9. Epub 2010 Jan 26.
- Balk E, Raman G, Chung M, et al; Effectiveness of management strategies for renal artery stenosis: a systematic review. Ann Intern Med. 2006 Dec 19;145(12):901-12. Epub 2006 Oct 24.
- Cooper CJ, Murphy TP, Matsumoto A, et al; Stent revascularization for the prevention of cardiovascular and renal events among patients with renal artery stenosis and systolic hypertension: rationale and design of the CORAL trial. Am Heart J. 2006 Jul;152(1):59-66.
- Nordmann A; Balloon angioplasty versus medical therapy for hypertensive patients with renal artery obstruction.; Cochrane Review Abstract and Plain Language Summary. Cochr Databas Syst Rev. 2006 Issue 2.
- White CJ, Jaff MR, Haskal ZJ, et al; Indications for renal arteriography at the time of coronary arteriography: a science advisory from the American Heart Association Committee on Diagnostic and Interventional Cardiac Catheterization, Council on Clinical Cardiology, and the Councils on Cardiovascular Radiology and Intervention and on Kidney in Cardiovascular Disease. Circulation. 2006 Oct 24;114(17):1892-5. Epub 2006 Oct 9.
- Schreiber MJ, Pohl MA, Novick AC; The natural history of atherosclerotic and fibrous renal artery disease. Urol Clin North Am. 1984 Aug;11(3):383-92.
Disclaimer: This article is for information only and should not be used for the diagnosis or treatment of medical conditions. EMIS has used all reasonable care in compiling the information but make no warranty as to its accuracy. Consult a doctor or other health care professional for diagnosis and treatment of medical conditions. For details see our conditions.
Dr Sean Kavanagh
Dr Colin Tidy
Prof Cathy Jackson